Dr. Michaelis covers some of her goals and ideas as the new Editor-in-Chief of The Hematologist and discusses the importance of using this medium to share data, important information, and stories of patients we meet along the way, to move forward the field of hematology.

Dr. Keel looks at a study that reviews the use of eltrombopag in combination with antithymocyte globulin and cyclosporine in refractory severe aplastic anemia treatment-naive patients, among other studies.

Dr. Moll discusses the ATTRACT Trial, which demonstrated that catheter-directed pharmacomechanical thrombolysis did not prevent the development of PTS in patients with acute proximal DVT, but increased the risk for major bleeding.

Drs. George and Conant review a study that shows that in patients with unexplained cytopenias, the detection of somatic mutations can stratify patients into being at low or high risk for developing myeloid malignancies. CHIP has clinical impact beyond increased risk for developing hematopoietic neoplasms and may have further implications in nonhematologic areas.

Dr. Jacobson looks at two randomized trials that demonstrate a benefit of antibody therapy against CD20 in new contexts in mantle cell lymphoma and follicular lymphoma 20 years after the initial FDA approval of rituximab to treat B cell lymphoma.